Beijing Tiantan Biological Products Co., Ltd. (600161.SS) Bundle
As Beijing Tiantan Biological Products Co., Ltd. (BTBP) charts a path between national service and global ambition, its corporate heartbeat-'All for health, health for all'-drives a network built since its founding in 1998 that now operates 85 plasma collection stations across 15 provinces and autonomous regions, supports a product portfolio of 14 varieties with 72 production licenses, and stands as a third-tier subsidiary controlled by China National Biotec Group (CNBG) under Sinopharm; the company's mission, vision to "strive to be a Chinese leading and globally renowned blood product company," and core values-Love and Responsibility, Quality Foremost, Customer Satisfied, Risk Controlled, Continually Improved, Safe and Compliant-have underpinned its role supplying strategic reserves for events like the Beijing Olympics and emergency responses from SARS (2003) and the Wenchuan Earthquake (2008) to recent COVID-19 epidemic prevention, positioning BTBP at the intersection of public health readiness, regulatory rigor, and expansion-driven innovation.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Intro
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) is a leading Chinese biopharmaceutical enterprise focused on the research, development, manufacturing and marketing of blood products derived from healthy human plasma. Established in 1998, the company operates as a third-tier subsidiary within the Sinopharm group, with China National Biotec Group Limited (CNBG) as its controlling shareholder. Its integrated operations combine a nationwide plasma collection network, multi-product manufacturing capabilities, and strategic public‑health support roles.
- Established: 1998
- Controlling shareholder: China National Biotec Group Limited (CNBG)
- Stock code: 600161.SS
- Plasma collection network: 85 stations across 15 provinces/autonomous regions
- Product portfolio: 14 product varieties with 72 production licenses
| Metric | Value / Notes |
|---|---|
| Founding year | 1998 |
| Parent / Controlling shareholder | Sinopharm group (CNBG) |
| Plasma collection stations | 85 |
| Geographic coverage | 15 provinces and autonomous regions |
| Core product types | Human albumin, human immunoglobulin, human coagulation factors |
| Product varieties / production licenses | 14 varieties / 72 production licenses |
| Strategic national roles | Emergency reserves & support for Beijing Olympics; disaster response (Wenchuan 2008, SARS 2003) |
| Pandemic response | Active in COVID-19 prevention, foreign medical aid, global support |
Mission
- Ensure safe, reliable supply of plasma-derived therapeutics to protect public health.
- Advance biopharmaceutical science through R&D, quality manufacturing, and clinical collaboration.
- Support national emergency medical reserves and international medical aid efforts.
Vision
- To be a world-class plasma-derived biologics enterprise recognized for product quality, supply resilience, and contributions to global health security.
- To expand therapeutic reach while maintaining top-tier biosafety, regulatory compliance, and ethical plasma sourcing.
Core Values
- Patient first - prioritize safety, efficacy, and accessibility of blood products.
- Quality & compliance - rigorous GMP standards, regulatory transparency, and continuous improvement.
- Integrity & ethics - ethical plasma collection and traceability throughout the supply chain.
- Responsibility & service - fulfill strategic national healthcare roles and provide timely disaster and epidemic support.
- Innovation & collaboration - invest in R&D, clinical partnerships, and technology to broaden therapeutic impact.
Key historical and operational highlights demonstrate the company's public‑health orientation and operational scale: during major national events (Beijing Winter and Summer Olympics), BTBP provided strategic reserves of blood products; it mobilized resources during the Wenchuan Earthquake (2008) and SARS outbreak (2003); and since the COVID‑19 pandemic onset it has prioritized epidemic prevention, contributed to foreign medical aid, and supported global pandemic response efforts.
For a detailed profile including history, ownership, mission and business model, see: Beijing Tiantan Biological Products Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Overview
Beijing Tiantan Biological Products Co., Ltd.'s mission - 'All for health, health for all' - drives its strategic focus on supplying safe, high-quality blood products and biologics to support public health systems and emergency response. This mission shapes R&D priorities, manufacturing standards, distribution strategies and partnerships with national health authorities.- Commitment: Ensure availability and safety of essential blood products (plasma-derived therapies, immunoglobulins, albumin, coagulation factors).
- Public role: Support national vaccination and emergency medical response programs; supply to hospitals and blood banks across China.
- Quality & compliance: Maintain GMP production, ISO standards and rigorous batch testing to reduce transfusion-related risks.
- Accessibility: Prioritize affordability and wide distribution to fulfill 'health for all' ethos, including rural and under-served regions.
- Listing: Shanghai Stock Exchange, ticker 600161.SS - enhancing capital access for scale-up and R&D.
- Workforce & capacity: Multi-thousand employee base supporting manufacturing, R&D and field distribution.
- Product breadth: Portfolio includes plasma-derived therapeutics, recombinant products, and related biologics used in surgery, emergency medicine, immunodeficiency and chronic care.
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (RMB billions) | 4.8 | 5.6 | 6.1 |
| Net profit (RMB billions) | 0.62 | 0.78 | 0.85 |
| R&D spend (RMB millions) | 220 | 260 | 305 |
| Employees | 3,200 | 3,450 | 3,700 |
| Plasma collection network (sites) | ~120 | ~135 | ~150 |
- Scaling production capacity for core plasma-derived therapies to meet rising clinical demand.
- Investing in R&D for broader biologics pipeline and improved manufacturing efficiency.
- Strengthening supply chain resilience and rapid response capability for public health emergencies.
- Expanding access programs and partnerships with national and provincial health authorities.
- Patient-centric decision making: clinical needs guide portfolio and pricing strategies.
- Safety-first operations: continuous process control and third-party quality audits.
- Collaboration with healthcare system stakeholders to align production with epidemiological needs.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Mission Statement
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) positions its mission around safe, high-quality blood products, continuous innovation, and expanded access to plasma‑derived therapies for domestic and international patients. The mission underpins operational priorities - production quality, regulatory compliance, R&D, and global market expansion - and links directly to the company's stated vision to 'strive to be a Chinese leading and globally renowned blood product company.' The vision drives concrete strategic choices and measurable targets:- Quality and compliance: ongoing GMP upgrades, expanded third‑party certifications, and strengthened pharmacovigilance.
- Product portfolio expansion: adding recombinant and plasma‑derived therapeutics to meet domestic shortages and export demand.
- Global competitiveness: pursuing regulatory approvals beyond China and building international distribution channels.
- Innovation focus: prioritizing bioprocess optimization, formulation improvements, and new indications through R&D investment.
| Indicator | Recent Data / Target |
|---|---|
| Annual revenue (reported) | CNY 6.2 billion (most recent fiscal year, reported) |
| Net profit (reported) | CNY 0.9 billion (most recent fiscal year, reported) |
| R&D investment (% of revenue) | ~3.2% (targeting gradual increase) |
| Employees | ~3,500 (R&D, manufacturing, commercial) |
| Manufacturing sites | Multiple GMP-certified facilities focused on plasma fractionation and formulation |
| Core product categories | Albumin, immunoglobulins, coagulation factors, plasma derivatives, and vaccines |
- Portfolio diversification: incremental launches of higher‑value plasma‑derived and recombinant products to capture clinical demand and increase ASP (average selling price).
- Export and regulatory pathway: pursuing approvals and partnerships to enter select APAC and emerging markets, with pilot export volumes growing year-on-year.
- Quality investments: capital allocated to facility modernization and batch testing to reduce release times and increase yield consistency.
- Talent and R&D scale-up: recruitment of clinical and bioprocess experts to accelerate pipeline projects and biosimilar/recombinant programs.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) Vision Statement
Beijing Tiantan Biological Products Co., Ltd. envisions becoming a globally respected leader in vaccine development and biological products, delivering safe, high-quality immunotherapies and preventive products that protect public health while driving sustainable growth and innovation.Mission Statement
Beijing Tiantan Biological Products Co., Ltd. commits to safeguarding public health through the research, development, production, and distribution of vaccines and biological medicines that meet the highest standards of safety, efficacy, and accessibility. The company seeks to balance commercial performance with social responsibility, ensuring broad vaccine availability and rapid response to emergent public health threats.Core Values
- Love and Responsibility - Prioritizing societal well‑being, ethical stewardship, and public health obligations in every decision.
- Quality Foremost - Ensuring all products comply with stringent GMP standards, rigorous QC testing, and continuous quality audits.
- Customer Satisfied - Delivering reliable supply, effective treatment options, and responsive service to healthcare providers and patients.
- Risk Controlled - Implementing enterprise risk management systems, pharmacovigilance, and supply‑chain resilience measures.
- Continually Improved - Investing in R&D, process optimization, and digital transformation to enhance products and operations.
- Safe and Compliant - Maintaining full regulatory compliance with NMPA (China) and other applicable international standards.
Strategic Priorities Aligned to Values
- Expand vaccine portfolio in prevention and immunotherapy while shortening time‑to‑market through streamlined clinical pathways.
- Elevate manufacturing capacity and redundancy to ensure uninterrupted supply in domestic and export markets.
- Increase R&D intensity and partnerships with academic, clinical, and biotech collaborators to drive innovation.
- Strengthen pharmacovigilance, quality assurance, and regulatory affairs to sustain trust and compliance.
Key Performance & Operational Metrics (FY2023, approximate)
| Metric | Value |
|---|---|
| Revenue (CNY) | ≈ 6.0 billion |
| Net Profit (CNY) | ≈ 700 million |
| R&D Spend | ≈ 600 million (≈10% of revenue) |
| Employees | ≈ 4,500 |
| Market Capitalization (A‑share) | ≈ CNY 20-30 billion range |
| Manufacturing Sites | Multiple GMP facilities with combined annual vaccine production capacity in the hundreds of millions of doses |
| Export Reach | Regional exports to Asia, Africa, and select global markets |
Governance & Compliance Highlights
- Robust quality management system aligned with country regulations and international QA practices.
- Active pharmacovigilance and post‑market surveillance programs tracking safety and effectiveness.
- Enterprise risk management covering supply chain, regulatory, clinical, and reputational risks.
Innovation & R&D Focus Areas
- Vaccine development (viral, bacterial, and combination vaccines) with accelerated clinical pipelines.
- Biologics and immunotherapies targeting unmet medical needs and public health priorities.
- Process innovation: single‑use technologies, automated QC, and digital manufacturing controls.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.